Non-Hodgkin's Lymphoma Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Phase I Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin's, Adult Intervention: Drug: SP-3164 Sponsor: Salarius Pharmaceuticals, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 7, 2023 Category: Research Source Type: clinical trials
Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Conditions: Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma Interventions: Biological: SIRPant-M; Radiation: External-beam radiotherapy (XRT) Sponsor: SIRPant Immunotherapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin Lymphoma Intervention: Biological: CHO-H01 Sponsor: Cho Pharma Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 18, 2023 Category: Research Source Type: clinical trials
